

CITATION REPORT

List of articles citing

LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT

DOI: 10.1016/s0022-5347(05)65866-1
Journal of Urology, 2001, 166, 927-931.

Source: <https://exaly.com/paper-pdf/32486802/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
93	Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. <i>International Journal of Impotence Research</i> , 2002 , 14, 61-4	2.3	34
92	Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. <i>Current Opinion in Neurology</i> , 2002 , 15, 271-8	7.1	63
91	The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. <i>Urology</i> , 2002 , 60, 12-27	1.6	130
90	Patient Choice is Critical in Managing Erectile Dysfunction. <i>European Urology Supplements</i> , 2002 , 1, 33-37	0.9	10
89	Editorial: Tachyphylaxis and Phosphodiesterase Type 5 Inhibitors. <i>Journal of Urology</i> , 2002 , 168, 207-207	2.5	10
88	Clinical update on sildenafil citrate. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 219-23	3.8	10
87	Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. <i>International Journal of Impotence Research</i> , 2002 , 14, 259-65	2.3	69
86	Sexual Functioning After Treatment for Early Stage Prostate Cancer. <i>Sexuality and Disability</i> , 2002 , 20, 239-260	1.3	4
85	Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. <i>Current Urology Reports</i> , 2003 , 4, 488-96	2.9	31
84	[Therapy of erectile dysfunction in 2005]. <i>Der Urologe</i> , 2003 , 42, 1330-6		3
83	Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. <i>Journal of Urology</i> , 2003 , 170, S15-8; discussion S19	2.5	60
82	Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. <i>Drugs</i> , 2003 , 63, 153-66	12.1	148
81	Sildenafil in erectile dysfunction: a critical review. <i>Current Medical Research and Opinion</i> , 2003 , 19, 241-62	2.5	77
80	Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. <i>Urology</i> , 2003 , 62, 110-5	1.6	90
79	Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. <i>Urology</i> , 2003 , 62, 121-5; discussion 125-6	1.6	250
78	Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. <i>Urology</i> , 2003 , 62, 1103-8	1.6	42
77	Salvage of sildenafil failures referred from primary care physicians. <i>Journal of Urology</i> , 2003 , 170, 2356-8	2.5	74

76	Long-term use of sildenafil. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 397-405	4	89
75	Heart Disease and Erectile Dysfunction. 2004 ,		
74	Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors. <i>Current Medical Research and Opinion</i> , 2004 , 20, 603-6	2.5	22
73	Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients. <i>Spinal Cord</i> , 2004 , 42, 643-8	2.7	58
72	Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. <i>Journal of Sexual Medicine</i> , 2004 , 1, 292-300	1.1	95
71	A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. <i>European Urology</i> , 2004 , 45, 499-507; discussion 507-9	10.2	76
70	Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. <i>Drugs</i> , 2004 , 64, 13-26	12.1	58
69	Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. <i>Urology</i> , 2004 , 63, 960-6	1.6	70
68	Histopathological effects of sildenafil citrate on rat corpus cavernosum. <i>Acta Histochemica</i> , 2004 , 106, 37-45	2	6
67	Drugs acting on the cerebral and peripheral circulations. <i>Side Effects of Drugs Annual</i> , 2004 , 209-212	0.2	
66	Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. <i>European Urology</i> , 2005 , 47, 87-91	10.2	94
65	Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 415-25; discussion 425-7	1.1	80
64	Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. <i>World Journal of Urology</i> , 2005 , 23, 385-92	4	37
63	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. <i>Urologic Clinics of North America</i> , 2005 , 32, 419-29, vi	2.9	34
62	Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. <i>Journal of Urology</i> , 2005 , 174, 646-50; discussion 650	2.5	98
61	In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. <i>Journal of Urology</i> , 2005 , 174, 1493-6	2.5	28
60	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,		
59	Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?. <i>Urology</i> , 2005 , 65, 224-30	1.6	10

58	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2005 , 99, 1501-10	4.6	70
57	Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. <i>Drugs and Aging</i> , 2006 , 23, 101-17	4.7	37
56	[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. <i>Actas Urológicas Españolas</i> , 2006 , 30, 67-79	0.7	7
55	Erectile dysfunction. <i>Journal of Urology</i> , 2006 , 175, S25-31	2.5	46
54	Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients. <i>International Journal of Impotence Research</i> , 2006 , 18, 302-5	2.3	5
53	Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. <i>International Journal of Impotence Research</i> , 2006 , 18, 550-8	2.3	17
52	Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2006 , 3, 504-11	1.1	5
51	Treating erectile dysfunction when PDE5 inhibitors fail. <i>BMJ, The</i> , 2006 , 332, 589-92	5.9	82
50	The management of phosphodiesterase-5 (PDE5) inhibitor failure. <i>Current Vascular Pharmacology</i> , 2006 , 4, 89-93	3.3	29
49	Expression, distribution and regulation of phosphodiesterase 5. <i>Current Pharmaceutical Design</i> , 2006 , 12, 3439-57	3.3	105
48	Phosphodiesterase type 5 inhibitors: extended duration of response as a variable in the treatment of erectile dysfunction. <i>International Journal of Impotence Research</i> , 2007 , 19, 119-23	2.3	27
47	Complications of Urologic Surgery and Practice. 2007 ,		2
46	Sildenafil in the treatment of erectile dysfunction. <i>Aging Health</i> , 2007 , 3, 295-303		2
45	Chronic sildenafil in men with diabetes and erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 451-64	5.5	24
44	The demise of sexological science is not imminent in the face of sexual medicine: commentary on "will medical solutions to sexual problems make sexological care and science obsolete?". <i>Journal of Sex and Marital Therapy</i> , 2007 , 33, 455-9	2.7	3
43	Centrally acting mechanisms for the treatment of male sexual dysfunction. <i>Urologic Clinics of North America</i> , 2007 , 34, 483-96, v	2.9	25
42	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , 2007 , 51, 75-88; discussion 89	10.2	73
41	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <i>European Urology</i> , 2007 , 52, 990-1005	10.2	45

40	Chronic dosing of phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , 2008 , 5, 65-69	1.2	
39	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. <i>European Urology</i> , 2008 , 53, 564-70	10.2	70
38	Does educational status affect a patient's behavior toward erectile dysfunction?. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1941-8	1.1	15
37	Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. <i>Journal of Andrology</i> , 2008 , 29, 3-14		39
36	Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. <i>Journal of Urology</i> , 2008 , 179, 1066-71	2.5	38
35	Sexual and marital aspects of old age: an update. <i>Sexual and Relationship Therapy</i> , 2008 , 23, 161-169	1.1	4
34	Endothelial effects of drugs designed to treat erectile dysfunction. <i>Current Pharmaceutical Design</i> , 2008 , 14, 3768-78	3.3	24
33	Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 235-42	3.2	7
32	Phosphodiesterase type 5 regulation in the penile corpora cavernosa. <i>Journal of Sexual Medicine</i> , 2009 , 6 Suppl 3, 203-9	1.1	21
31	Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. <i>Andrologia</i> , 2009 , 41, 169-75	2.4	45
30	A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. <i>BJU International</i> , 2010 , 105, 1634-9	5.6	26
29	Vardenafil: efficacy, tolerability and future directions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 553-62	5.5	3
28	Dose-dependent effects of sildenafil on post-ischaemic left ventricular function in the rat isolated heart. <i>Journal of Pharmacy and Pharmacology</i> , 2010 , 62, 346-51	4.8	15
27	Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. <i>European Urology</i> , 2010 , 57, 522-8	10.2	29
26	Editorial comment on: Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. <i>European Urology</i> , 2010 , 57, 528-9	10.2	
25	Couples' Reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. <i>Journal of Sexual Medicine</i> , 2012 , 9, 857-65	1.1	23
24	Rehabilitation of the cavernous smooth muscle in patients with organic erectile dysfunction. <i>Andrologia</i> , 2012 , 44, 125-9	2.4	1
23	Angiotensin II increases corpus cavernosal contractility and oxidative stress in partial bladder outlet obstructed rabbits: relevance to erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1251-8	1.1	3

22	Kidney Transplantation. 2014 ,		2
21	Sexual Function in Men and Women with Diabetes. 2016 , 716-730		
20	Aging related erectile dysfunction-potential mechanism to halt or delay its onset. <i>Translational Andrology and Urology</i> , 2017 , 6, 20-27	2.3	37
19	Erectile dysfunction among male adult entertainers: a survey. <i>Translational Andrology and Urology</i> , 2018 , 7, 926-930	2.3	1
18	Back to Stir It Up: Erectile Dysfunction in an Evolutionary, Developmental, and Clinical Perspective. <i>Journal of Sex Research</i> , 2019 , 56, 378-390	4	7
17	Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review. <i>International Journal of Impotence Research</i> , 2021 , 33, 16-42	2.3	1
16	Sexual Function in Men and Woman with Diabetes. 743-759		1
15	Reproductive Complications and Sexual Dysfunction in Cancer Survivors. 2007 , 251-271		10
14	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 403-14	4	36
13	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 439-49	4	12
12	Editorial: Tachyphylaxis and Phosphodiesterase Type 5 Inhibitors. <i>Journal of Urology</i> , 2002 , 207	2.5	
11	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. 2004 , 35-47		
10	Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. 2004 , 89-116		
9	Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors. 2005 , 409-421		
8	Erectile Dysfunction Assessment and Management in Primary Care Practice. 2005 , 149-183		
7	Sildenafil. 2006 , 3133-3137		
6	DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. 2009 , 431-448		
5	Urologic Issues in the Renal Transplant Patient. 2014 , 341-353		

4	Phosphodiesterase type V inhibitors. 2016 , 734-742		
3	Reproductive Complications and Sexual Dysfunction in the Cancer Patient. 2006 , 1589-1609		
2	Does treatment of erectile dysfunction with PDE 5 inhibitor Tadalafil improve quality of life in male patients with compensated chronic liver disease? A prospective pilot study. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 ,	4.1	○
1	Electroacupuncture for psychogenic erectile dysfunction: A resting-state functional magnetic resonance imaging study exploring the alteration of fractional amplitude of low frequency fluctuation. 17,		○